- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Amgen's Blincyto Approved for B-Cell ALL
Blincyto, which was considered a promising immunotherapy with a novel mechanism of action, was approved 5 months prior to its PDUFA date.
The FDA today announced the approval of the anti-CD19 molecule, Blincyto (blnatumomab), in the treatment of patients with a rare form of acute lymphoblastic leukemia, Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL). This new immunotherapy boosts T-cells of the body's immune system to fight the leukemia. Intended for use in relapsed or refractory patients, Blincyto was developed by the biotechnology company Amgen.
“Immunotherapies, especially Blincyto with its unique mechanism of action, are particularly promising for patients with leukemia,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Recognizing the potential of this novel therapy, the FDA worked proactively with the sponsor under our breakthrough therapy designation program to facilitate the approval of this novel agent.”
Preliminary results with the drug were deemed promising by the FDA, which resulted in it being granted a breakthrough therapy designation, a priority review, and orphan product designation. Safety and efficacy studies of Blincyto showed that 32% of 185 adults were in complete remission for 6.7 months. The approval, which includes a Risk Evaluation and Mitigation Strategy for Blincyto, comes 5 months ahead of the PDUFA date.
Around the Web
FDA approves Blincyto to treat a rare form of acute lymphoblastic leukemia
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Decisions and Precision in Value-Based Cancer Care
January 7th 2025An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More
